Fig. 2: Distribution of serum t-tau, serum NfL and CSF NfH in the diagnostic groups. | Nature Communications

Fig. 2: Distribution of serum t-tau, serum NfL and CSF NfH in the diagnostic groups.

From: Phosphorylated tau 181 and 217 are elevated in serum and muscle of patients with amyotrophic lateral sclerosis

Fig. 2

A Distribution of serum t-tau in the total cohort of ALS [n = 141, including 14 cases with (A+) and 104 cases without AD co-pathology (A-)], AD cases (n = 104) and disease controls (DCo, n = 90). B Serum t-tau in the diagnostic groups stratified according to the individual cohorts (Halle cohort: 58 ALS, 60 AD and 32 disease controls; Milan cohort: 66 ALS, 19 AD and 21 disease controls; Mannheim 1 cohort: 17 ALS and 12 disease controls; Mannheim 2 cohort: 25 AD and 25 controls). C Distribution of serum NfL in the total cohort of ALS [n = 152, including cases with (A+) and cases without AD co-pathology (A-)], AD cases (n = 111) and DCo (n = 99). D Serum NfL in the diagnostic groups stratified according to the individual cohorts (Halle cohort: 63 ALS, 66 AD and 40 disease controls; Milan cohort: 67 ALS, 20 AD and 22 disease controls; Mannheim 1 cohort: 22 ALS and 12 disease controls; Mannheim 2 cohort: 25 AD and 25 controls). E Distribution of CSF NfH in the total cohort of ALS [n = 152, including cases with (A+) and cases without AD co-pathology (A-)], AD cases (n = 111) and DCo (n = 99). F CSF NfH in the diagnostic groups stratified according to the individual cohorts (Halle cohort: 63 ALS, 66 AD and 40 disease controls; Milan cohort: 67 ALS, 20 AD and 22 disease controls; Mannheim 1 cohort: 22 ALS and 12 disease controls; Mannheim 2 cohort: 25 AD and 25 controls). Biomarker levels are reported on a logarithmic scale. Dots represent single data points. Horizontal lines represent the median values, the lower and upper lines correspond to the first and third quartiles, and the vertical line is the interquartile range. Biomarker differences between groups were assessed by Mann–Whitney or Kruskal–Wallis followed by Dunn’s post hoc test (adjustment for multiple comparisons). Two-sided p-values are reported. AD Alzheimer’s disease, ALS amyotrophic lateral sclerosis, ALS A+ amyotrophic lateral sclerosis with AD copathology, ALS A- amyotrophic lateral sclerosis without AD copathology, AUC area under the curve, CSF cerebrospinal fluid, DCo disease controls, Mann 1 Mannheim 1 cohort, Mann 2 Mannheim 2 cohort, NfH neurofilament heavy chain protein, NfL neurofilament light chain protein, t-tau total tau protein. Source data are provided as a Source Data file.

Back to article page